GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.20
Bid: 5.10
Ask: 5.30
Change: -0.05 (-0.95%)
Spread: 0.20 (3.922%)
Open: 5.20
High: 5.30
Low: 5.20
Prev. Close: 5.25
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue

Wed, 27th Mar 2024 11:02

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Norman Broadbent PLC, up 13% at 8.75 pence, 12-month range 4.50p-9.32p. The London-based recruitment firm swings to a pretax profit in 2023 of GBP309,000 from a loss of GBP338,000 in 2022. This tracks revenue rising 41% to GBP12.3 million from GBP8.7 million, partially offset by operating expenses rising 34%to GBP10.2 million from GBP7.6 million and cost of sales rising 21% to GBP1.7 million from GBP1.4 million. Chief Executive Officer Kevin Davidson comments: "We have taken the opportunity to invest further in the Company, hiring exceptional people and building our platform to take advantage of the market rebound when it comes. Our ambition remains steadfast and we will continue to pursue our aggressive growth strategy, whilst remaining profitable and cash positive, both organically and potentially through synergistic M&A opportunities...Supported by our considerable brand strength and market leading processes and technologies, we are well-positioned for continued success."

----------

Allergy Therapeutics PLC, up 11% at 3p, 12-month range 0.37p-3.20p. In the six months that ended December 31, the Sussex, England-based biotechnology company reports pretax loss widening to GBP14.9 million from GBP8.2 million a year earlier. Revenue falls 16% to GBP33.6 million from GBP39.9 million, while financial expenses soar to GBP3.2 million from GBP398,000. Chief Executive Officer Manuel Llobet comments: "2023 has been an important year, marked by a highly focused approach to our business priorities, and a steadfast commitment to our Grass and Peanut allergy research & development programmes. We have navigated the challenges of last year, resulting in more streamlined operations and improved cost-effectiveness. This progress starts to pave the way towards a return to growth." Allergy Therapeutics also notes that its lenders have agreed that a further GBP15 million may be drawn from the existing GBP40 million amended loan facility from the second quarter of calendar 2024, with the first GBP7.5 million having already been drawn down. It says this extends its cash runway into the first quarter of its financial 2025. The lenders are major shareholders SkyGem Acquisition, which is an affiliate ZQ Capital Management, alongside Southern Fox Investments.

----------

AIM - LOSERS

----------

Infrastructure India PLC, down 80% at 0.10p, 12-month range 0.10p-1.27p. In the six months that ended September 30, the infrastructure fund investing directly into assets in India reports pretax loss narrowing to GBP31.5 million from GBP62.2 million a year earlier, largely driven by foreign exchange loss narrowing to GBP3.7 million from GBP40.8 million. Shares restarted trading on Wednesday after publishing its annual results for the financial year ended March 31 on Tuesday. During this period, pretax loss widened to GBP59.2 million from GBP48.4 million a year earlier. The company says: "The group has prepared the interim results on a basis other than going concern due to the uncertainty in relation to the timing of potential transactions, ultimate receipt of sale proceeds and the specifics of any deferred consideration. This basis was considered the most appropriate method for the reporting period."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
23 Jul 2015 08:38

Allergy Therapeutics Expects Revenue Growth Despite Euro Weakness

Read more
6 Jul 2015 07:43

Allergy Therapeutics dust mite study yields positive results

Pharmaceutical group Allergy Therapeutics has announced positive results from a clinical study for the treatment of house dust mite allergy. Results of the observational one-year follow-up study of Acarovac Plus showed that there were no adverse effects to the tolerability of the product, while ther

Read more
6 Jul 2015 07:36

Allergy Therapeutics Gets Good Results From Acarovac Plus Study

Read more
2 Jul 2015 08:07

Allergy Therapeutics To Host Allergy Conference In Amsterdam

Read more
25 Jun 2015 07:40

Allergy Therapeutics Resumes Allergy Treatment US Clinical Programme

Read more
5 Jun 2015 11:14

Allergy Therapeutics buys Alerpharma for 3.8m euros

Specialty pharmaceutical company Allergy Therapeutics said on Friday that it has agreed to buy Alerpharma SA for an initial consideration of €3.8m. Alerpharma wholly owns the Spanish-based allergy immunotherapy company Instituto de Immunologia y Alergia (Inmunal),which is a spin-out of biopharmaceut

Read more
5 Jun 2015 10:14

Allergy Therapeutics Acquires Alerpharma For Up To EUR5.8 Million

Read more
10 Mar 2015 12:42

UK MIDDAY BRIEFING: The Man From The Pru To Leave On High Note

Read more
10 Mar 2015 12:05

UK WINNERS & LOSERS: Oil Stocks, Gold Miners Hit By Price Weakness

Read more
10 Mar 2015 10:30

Allergy Therapeutics Raises GBP20.8 Million In Share Placing (ALLISS)

Read more
2 Mar 2015 09:46

Allergy Therapeutics Ups Profit, Revenue, Market Share In First Half

Read more
12 Jan 2015 08:52

Allergy Therapeutics To Post 4% Rise In First-Half Revenue

Read more
30 Sep 2014 10:35

Allergy Therapeutics Extends Convertible Loan With Abbott Labs' CFR

Read more
22 Sep 2014 09:06

Allergy Therapeutics Profit Up, Optimistic For Future On US Prospects

Read more
22 Sep 2014 05:20

UK Earnings, Trading Statements Calendar - Week Ahead

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.